Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma

Richa Rathore, Brian Van Tine

Research output: Contribution to journalArticlepeer-review

Abstract

The rate-limiting enzyme of serine biosynthesis, 3-phosphoglycerate dehydrogenase (PHGDH), contributes to rapid growth and proliferation when it is overexpressed in cancer. We recently described the metabolic adaptations that occur upon PHGDH inhibition in osteosarcoma. PHGDH inhibition causes metabolite accumulation that activates the mechanistic target of rapamycin (mTOR) signaling, sensitizing osteosarcoma to non-rapalog mTOR inhibition.

Original languageEnglish
Article number1902250
JournalMolecular and Cellular Oncology
Volume8
Issue number3
DOIs
StatePublished - 2021

Keywords

  • PHGDH
  • mTORC1
  • methotrexate
  • osteosarcoma
  • perhexiline
  • serine

Fingerprint

Dive into the research topics of 'Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma'. Together they form a unique fingerprint.

Cite this